# 10/570734

14-20 REC'E FULLIO OF MAR 2006'
Docket No. 4126-4037

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ariadna Fernandez Donis, Ernest Giralt Lledó, Carolina Gracia Cantador, Pilar López Rodríguez, Sonia Varon Colomer, Carmen Cuevas Marchante, Ángel López Macia, Andrés Francesch Solloso, José-Carlos Jiménez Garcia, Miriam Royo Expósito, and Fernando Albericio Palomera								
Serial No.	: TBA	Group Art Unit:	TBA					
Filed:	HEREWITH	Examiner:	TBA					
For:		NEW ANTITUMORAL COMPOUNDS						
Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450								
Attn: DO/	EO/US							
Sir:	·							
	This Information Disclosure Sta	tement is filed in acco	ordance with 37 C.F.R.					
§§1.56, 1.	97 and 1.98. The items listed on Form	m PTO-1449, a copy o	of which is enclosed, are					
made of re	ecord to assist the Patent and Tradema	ark Office in its exam	ination of this application.					
The Examiner is respectfully requested to fully consider the items and to independently ascertain								
their teach	ung.							
	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:							
2.	For each of the following items listed	d on the enclosed copy	y of Form PTO-1449 that is					
	not in the English language, a concise incorporated in the specification of the	e explanation of the re	elevance of that item is					
	Any copy of the items listed on the enclosed copy of Forms PTO-1449A and PTO-1449B that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No.							

4.	$\boxtimes$	No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:					
		$\boxtimes$	37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits.				
5.		sin in j All	fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement ce it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified paragraph 4 above but before the mailing date of a final action or a Notice of owance (where there has been no prior final action), and is accompanied by one of certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.				
6.		it is par	see is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in agraph 4 above but before the mailing date of a final action or a notice of owance (where there has been no prior final action):				
			A check in the amount of \$180.00 is enclosed in payment of the fee.				
			Charge the fee to Deposit Account No. <u>13-4500</u> , Order No A DUPLICATE COPY OF THIS SHEET IS ATTACHED.				
7.		it is	see is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final son or a notice of allowance, whichever comes first, but before payment of the issue and is accompanied by:				
		a.	one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and				
		b.	the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.				
8.		Thi	s Information Disclosure Statement is being filed in compliance with:				
	-	a.	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);				
		b.	37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).				

Serial No. TBA The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 c. IAP20 Rec'd PCT/PTO 0 6 MAR 2006 below.

I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 10. This document is accompanied by \( \sqrt{\operation} \) a Search Report \( \sqrt{\operation} \) Communication which was cited in a corresponding | PCT or | Foreign counterpart application 11. A check in the amount of \$ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p). Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No. \_\_\_\_\_. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.  $\boxtimes$ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4126-4037. Respectfully submitted, MORGAN & FINNEGAN, L.L.P.

Dated: March 6, 2006

By:

Kenneth H. Sonnenfeld // Michael A.

Registration No. 33,285 // 53,913

Correspondence Address:

MORGAN & FINNEGAN, L.L.P. 3 World Financial Center New York, NY 10281-2101 (212) 415-8700 Telephone (212) 415-8701 Facsimile

INFORM  Examiner Initial		ORM PTO-1449A ON DISCLOSURE CITA  U.S. P  Patent/Publication Num	PATENT /	Applic Ariadn Pilar L Marcha Jiméne Palomo Filing Herew	ant: a Fernanc ópez Rod ante, Áng ez Garcia, era Date: ith	dez Donis, ríguez, Soi el López N Miriam Ro	nia Va ⁄Iacia, oyo Ex	Giralt Lle ron Colon Andrés Fr pósito, an Group A TBA	edó, Carolina Grac ner, Carmen Cueva rancesch Solloso, Jo nd Fernando Alberi Art Unit:	a Cantador, s osé-Carlos	
		-			-						
					<u></u>						
	:	and the second of the second o	FOREIGN		ENT DO	CUMENT	s		; r		
Examiner Initial		Patent Number	Public Da			Country		Copy Filed	Transla	ion	
	1	WO 01/58934 A2	16 Aug.	2001	PCT			☐ Yes	☐ Yes ☐ No ☐ A	bstract ⊠N/A	
	2.	WO 03/033012 A1	24 Apr.	2003	PCT			☐ Yes	Yes No A	bstract ⊠N/A	
	3.	WO 2004/035613 A2	29 Apr.	2004	PCT			☐ Yes	☐ Yes ☐ No ☐ A	bstract ⊠N/A	
	4.							☐ Yes	☐ Yes ☐ No ☐ A	bstract □N/A	
	5.							☐ Yes	☐ Yes ☐ No ☐ A	bstract □N/A	
	6.							☐ Yes	Yes No A	bstract N/A	
Examiner			<del></del> -	<del></del>	Date Cor	nsidered					
EXAMINER:	Initial	if reference considered, whether or	r not citation i	s in confe	ormance wit	h MPEP §60	9.				
-	Draw line through citation if not in conformance and not considered.  Include copy of this form with pext communication to Applicant.										

Page 1 of 1

#### **FORM PTO-1449B**

# INFORMATION DISCLOSURE CITATION

Attorney Docket:	Serial No TBA		5	70	7	3	4
4126-4037 Applicant:	IBA	62 62 A	-	-	_	_	

Ariadna Fernandez Donis, Ernest Giralt Lledó, Carolina Gracia Cantador, Pilar López Rodríguez, Sonia Varon Colomer, Carmen Cuevas Marchante, Ángel López Macia, Andrés Francesch Solloso, José-Carlos Jiménez Garcia, Miriam Royo Expósito, and Fernando Albericio Palomera

Filing Date: Group Art Unit: Herewith TBA

### NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, Examiner Cite No.1 journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where Initials\* published. Hamann et al., "Kahalalides: Bioactive Peptides From A Marine Mollusk Elysia Rufescens And Its Algal Diet Bryopsis sp.," J. Org. Chem., Vol. 61, pgs. 6594-6600, 1996. 1. López-Macià et al., "Synthesis And Structure Determination Of Kahalalide F," J. Am. Chem. 2. Soc., Vol. 123, No. 46, pgs. 11398-11401, 2001. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20.

Examiner	Date	
Signature	Considered	

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.